www.fida-tech.com

CSL Behring adopts FIDA for accurate characterization of molecular interactions based on direct, in-solution measurements

Company: CSL Behring, Bern, Switzerland.

Team members: Giuseppina Fascellaro, Marius Lötscher

Products used: FIDAlyzer including consumables (vials, capillaries etc.)

"In benchmarking tests, FIDA has enabled CSL Behring to assess protein binding in solution with results comparable to current in-house technologies based on surface coupling of one binding partner. We are looking forward to using FIDA for the molecular interaction characterization of our innovative plasma-derived drug candidates." ***Giuseppina Fascellaro, Ph.D., Research Scientist, CSL Behring, Bern.***

Background: For global leader, CSL Behring, it is essential to work with as complete and accurate data as possible. Most of their products are based on plasma-derived proteins, which requires analytical methodologies that are able to address protein concentration and binding in solution.

The Challenge: CSL Behring has been looking for alternative technologies for binding analysis of proteins in solution to complement current techniques based on surface immobilization. It has been a critical objective for CSL Behring to be able to include data generated under more native conditions in assessment and documentation of product performance and quality. Initially, the main focus has been on identifying systems for obtaining more qualified data on interactions of plasma-derived proteins.

The Solution: CSL Behring has after extensive comparative studies implemented our FIDA platform to assess binding of plasma protein based on direct in-solution measurements. The assay performance proved in all cases comparable to current techniques with additional data, including molecular size. CSL Behring will in the future use FIDA for molecular interaction characterization of its plasma-derived drug candidates.

Products used: CSL Behring uses the standard, fully automated FIDA platform with fast assay setup and validation. The 21 CFR part 11 compliant software allows methods to be transferred to a regulated environment. It accepts multiple 96 well plates, vials with inserts and standard vials. Due to the automation, it may be left for unattended operation for hours to days.